Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: J Cell Biochem. 2013 Jan;114(1):67–78. doi: 10.1002/jcb.24301

Fig. 6.

Fig. 6

Effects of ZA on hematopoietic cell composition. To investigate the effects of ZA on hematopoiesis and progenitor cells, bone marrow and blood cells of 4-week-old mice were analyzed; A: no alteration in the bone marrow CD41+ mature hematopoietic composition with ZA treatment versus vehicle(VEH) control; B: blood cell count of white blood cells (WBC), red blood cells (RBC), and platelets (PLT) were not altered with ZA treatment; C: sixteen-week-old mice were treated with ZA or vehicle (VEH) for 4 weeks and bone marrow cells were collected and LSK Flt3+ and Flt3− were analyzed by flow cytometry. D–E: Endothelial progenitor cells (CD11b− CD34+ Flt3+) were analyzed over time to investigate the effects of ZA in bone marrow and mobilization to the peripheral blood; (D) EPCs in the bone marrow were significantly decreased at 3 weeks of ZA treatment but not significantly different at 4 weeks; (E) EPCs in the peripheral blood were not altered by ZA treatment (*P <0.05). Data are presented as mean ± SEM, n = 8/gp (T/C) treatment/control.